Business● Low1h ago · Nov 6, 2026, 4:25 AM
IRhythm plans Zio MCT FDA filing in 2027 while raising 2026 revenue outlook to $890M-$895M
GlobeAlert Desk · curated from Seeking Alpha Tech · global
IRhythm intends to file Zio MCT with the FDA in 2027 and has increased its 2026 revenue outlook to $890 million-$895 million. This indicates the company's product development timeline and financial projections.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business14m agoHong Kong’s Exchange Fund earnings tumble 74% as HKMA warns of more market turbulenceSouth China Morning PostBusiness14m agoCarlyle expects at least $20B of Q4 inflows as it targets about $60B for full-year 2026Seeking Alpha TechBusiness14m agoAnthropic's $1.5T valuation under pressure as major investors signal skepticism, WSJ reportsSeeking Alpha TechBusiness14m agoKLX Energy Services Non-GAAP EPS of -$0.44 misses by $0.09, revenue of $186M beats by $3.5MSeeking Alpha Tech